[New oral anticoagulants: better than vitamin K antagonists?].
Many years of practical use and intensive scientific research have allowed vitamin K antagonists to become a cornerstone of treatment of internal diseases. Nevertheless, limitations in pharmacokinetics and -dynamics of vitamin K antagonists and the availability of new drugs in regard to a targeted anticoagulation therapy ask for a new review of the situation. Proof of effectiveness for the perioperative prophylaxis of venous thrombosis after hip and knee replacement has already been achieved for the direct thrombin inhibitor dabigatran etexilate as well as for the factor Xa inhibitors rivaroxaban und apixaban compared to low molecular weight heparins. These new drugs are now also investigated in patients with internal diseases. For the long-term application (6 or 12 months) concerning the treatment of venous thrombosis and/or stroke prophylaxis in patients with atrial fibrillation data is already available for the direct thrombin inhibitor dabigatran etexilate. Depending on its dosage its effectiveness in comparison with vitamin K antagonists is equal or even better without disadvantages in safety. However, vitamin K antagonists will remain the standard oral anticoagulation until open questions regarding e.g. insufficient therapy adherence (with termination rates up to 20%) or problems with drug interactions of the new competitive products have been completely answered.
Völler
H
H
FESC, Klinik am See, Rehabilitationszentrum für Innere Medizin, Seebad 84, Rüdersdorf, Germany. heinz.voeller@klinikamsee.com
Alban
S
S
Westermann
D
D
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D058833:Antithrombin Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use; D000069552:Rivaroxaban; D020521:Stroke / Q000517:prevention & control*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D058833:Antithrombin Proteins; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013876:Thiophenes; D014812:Vitamin K; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran
Circulation. 2010 Apr 6;121(13):1523-32
20368532
Stroke. 2009 Apr;40(4):1410-6
19182090
N Engl J Med. 2008 Jun 26;358(26):2827-9
18579818
Stroke. 2009 Jan;40(1):235-40
18757287
Curr Pharm Des. 2008;14(12):1152-75
18473863
Thromb Haemost. 2010 Apr;103(4):833-40
20135077
Thromb Haemost. 2010 Jul;104(1):49-60
20539909
Hamostaseologie. 2005 Feb;25(1):39-49
15711719
Hamostaseologie. 2007 Sep;27(4):282-9
17938768
Am Heart J. 2010 Mar;159(3):340-347.e1
20211293
Eur Heart J. 2004 Aug;25(16):1385-94
15302102
Drug Metab Dispos. 2009 Jan;37(1):74-81
18832478
Chest. 2008 Jun;133(6 Suppl):381S-453S
18574271
N Engl J Med. 2009 Sep 17;361(12):1139-51
19717844
N Engl J Med. 2009 Dec 10;361(24):2342-52
19966341
Chest. 2008 Jun;133(6 Suppl):299S-339S
18574269
Am Heart J. 2010 Mar;159(3):331-9
20211292
Expert Opin Investig Drugs. 2008 Dec;17(12):1937-45
19012508
Ann Intern Med. 2007 Jun 19;146(12):857-67
17577005
Lancet. 2006 Feb 4;367(9508):404-11
16458764
Eur Heart J. 2004 Aug;25(16):1395-404
15321697
J Am Coll Cardiol. 2007 Nov 27;50(22):2156-61
18036454
Stroke. 2001 Feb;32(2):392-8
11157172
Europace. 2009 Apr;11(4):423-34
19153087
Eur Heart J. 2009 Dec;30(24):2969-77c
19535417
Lancet. 2010 Mar 6;375(9717):807-15
20206776
Eur Heart J. 2005 Nov;26(22):2422-34
16204266
Eur Heart J. 2006 Aug;27(16):1979-2030
16885201
Thromb Haemost. 2010 Feb;103(2):360-71
20024501
Drug Metab Dispos. 2010 Mar;38(3):448-58
19940026
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):41-8
16254201
Thromb Haemost. 2010 Jan;103(1):34-9
20062925